| 0.4302 -0.007 (-1.65%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.78  |
1-year : | 0.96 |
| Resists | First : | 0.67 |
Second : | 0.82 |
| Pivot price | 0.5 |
|||
| Supports | First : | 0.41 | Second : | 0.34 |
| MAs | MA(5) : | 0.46 |
MA(20) : | 0.53 |
| MA(100) : | 1.58 |
MA(250) : | 14.23 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 13.1 |
| RSI | RSI(14): 24.2 |
|||
| 52-week | High : | 62.22 | Low : | 0.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRI ] has closed above bottom band by 2.7%. Bollinger Bands are 88.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.45 | 0.45 - 0.45 |
| Low: | 0.41 - 0.42 | 0.42 - 0.42 |
| Close: | 0.42 - 0.43 | 0.43 - 0.43 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Thu, 25 Apr 2024
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - GlobeNewswire
Tue, 16 Apr 2024
GRI Bio secures key Korean patent for NKT cell modulators - Investing.com Nigeria
Tue, 16 Apr 2024
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of ... - Yahoo Finance
Mon, 08 Apr 2024
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ... - Yahoo Finance
Mon, 01 Apr 2024
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, 04 Mar 2024
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 143 (K) |
| EPS | -28.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -417 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 1.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|